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Germline mutations in the gene coding for tumor protein p53
(TP53, best known as p53) are associated with the
Li-Fraumeni syndrome, a dominant hereditary disorder
characterized by an increased predisposition of patients to the
development of various tumors relatively early in life.
In addition, TP53 is affected by somatic loss-of-function
mutations in a large fraction (450%, according to current
estimates) of human cancers all confounded.1 Finally, several
other molecular defects causally associated with malignant
transformation or tumor progression result in the functional
inactivation of the p53 system. As a notable example,
multiple neoplasms express increased levels of MDM2 proto-
oncogene, E3 ubiquitin protein ligase (MDM2), resulting in an
accrued degradation of p53 by the proteasome.2 These
observations indicate that the loss of p53 functions favors the
establishment and/or progression of various malignancies.
Throughout the past 25 years, p53 has been the subject of
intense investigation, revealing a wide panel of mechanisms by
which this protein exerts robust oncosuppressive functions.3
Initially, p53 was recognized for its ability to respond to DNA
damage by transactivating several genes that regulate cell cycle
progression (e.g., CDKN1A) and apoptotic cell death (e.g.,
BAX), hence preventing the propagation of potentially trans-
forming genetic defects.4 Later, stress-activated p53 turned out
to participate in the activation of mitochondrial apoptosis by
physically interactingwith pro- and antiapoptoticmembers of the
Bcl-2 protein family (such as BAX, BCL-2 and BCL-XL), thereby
favoring the elimination of potentially dangerous cells via
transcription-independent mechanisms.5 More recently, several
studies demonstrated that p53 mediates oncosuppressive
effects not only when cells are confronted with sources of
stress, but also in physiological conditions. In particular, p53 has
been attributed with a key role in the preservation of
physiological bioenergetic metabolism, mostly linked to its
capacity to regulate the transcription of some metabolic
enzymes.6,7 Now, the research group lead by Paolo Pinton
(University of Ferrara; Ferrara, Italy) identified yet another
mechanism by which p53 mediates transcription-independent
oncosuppressive functions (Figure 1).8,9 In particular, Giorgi and
colleagues demonstrated that cytoplasmic p53 physically
stimulates the accumulation of Ca2+ ionswithin the endoplasmic
reticulum (ER) by physically interacting with ATPase, Ca++
transporting, cardiac muscle, fast twitch 1 (ATP2A, best known
as SERCA). This increases the efficiency of the transfer of Ca2+
ions between the ER and mitochondria, augmenting the
propensity of (pre)malignant cells exposed to oncogenic or
chemotherapeutic stress to succumb to apoptosis.8,9
Previous results from the same group indicated that the
extranuclear pools of several oncosuppressor proteins pre-
ferentially localize to the so-called mitochondria-associated
ER membranes (MAMs),10,11 which are sites of physical and
functional connection between the ER and the mitochondrial
network. Thus, Giorgi and co-workers set out to study the
localization of cytoplasmic p53 in human colorectal carcinoma
HCT 116 cells exposed to doxorubicin (an immunogenic DNA-
damaging agent routinely employed for the treatment of
various cancers),12,13 or oxidative stress (as induced by the
administration of hydrogen peroxide).14,15 In line with pre-
cedent works, p53 accumulated in the cytoplasm of HCT 116
cells treated with doxorubicin or hydrogen peroxide, a
phenomenon that was particularly evident when the ER and
MAMswere studied as subcytoplasmic fractions.9 Of note, the
ability of a nonlethal dose of doxorubicin to promote the
accumulation of p53 at the ER was sufficient to render
Trp53+/+ mouse embryonic fibroblasts (MEFs) completely
sensitive to a partially lethal dose of hydrogen peroxide.
Conversely, Trp53−/− MEFs were totally resistant to hydrogen
peroxide-induced cell death, irrespective of the preadministra-
tion of doxorubicin.9 These data confirmed the role of p53 in
apoptosis induced by oxidative stress while highlighting a
potential implication of the ER in this process.
Given the implication of Ca2+ fluxes between the ER and
mitochondria in the control of mitochondrial apoptosis,16,17
Giorgi and colleagues investigated the effects of the absence
of p53 on reticular Ca2+ homeostasis. They found that
Trp53-/- MEFs exhibit lower steady-state reticular Ca2+ levels
than their Trp53+/+counterparts, resulting in decreased Ca2+
mobilization and mitochondrial accumulation in response to
ATP (a purinergic receptor agonist that is commonly employed
to trigger cytosolic Ca2+ waves) or hydrogen peroxide. Similar
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results were obtained with HCT 116 cells, p53-overexpressing
human cervical carcinoma HeLa cells and Trp53−/− MEFs
reconstituted with wild-type p53. Moreover, Trp53+/+ MEFs,
but not their Trp53−/− counterparts, responded to hydrogen
peroxide with a fragmentation of the mitochondrial network,
a phenomenon that could be drastically exacerbated by the
preadministration of doxorubicin (which per se failed to do
so).9 Importantly, the authors excluded the involvement of the
transcriptional activity of p53 in this process by several
experimental strategies, including (1) the pharmacological
blockade of transcription with α-amanitin, alone or combined
with the p53 inhibitor pifithrin α, to Trp53+/+ MEFs; (2) the
reconstitution of Trp53−/− MEFs with p53 mutants lacking the
nuclear localization signal (NLS); and (3) the reconstitution of
Trp53-/- MEFs with an NLS-deficient p53 variant specifically
addressed to the ER. Moreover, Giorgi and colleagues
demonstrated that various naturally occurring p53 mutants,
such as p53R175H and p53R273H, are unable to restore reticular
Ca2+ homeostasis in Trp53−/− MEFs, while the WT protein
efficiently does so. Accordingly, p53WT, but not p53R175H and
p53R273H, increased the sensitivity of Trp53−/− MEFs to
oxidative stress back to the levels of their Trp53+/+
counterparts.9 These data suggest that the cytoplasmic pool
of p53 regulates the accumulation of Ca2+ ionswithin the ER, a
process that influences the sensitivity of the mitochondrial
network to the induction of apoptosis.
Next, Giorgi and colleagues set out to investigate the
molecular mechanisms by which cytoplasmic p53 influences
reticular Ca2+ homeostasis. Pull-down assays in human
non-small cell lung carcinoma H1299 cells engineered to
overexpress p53 as well as co-immunoprecipitation experi-
ments in Trp53+/+MEFs revealed that p53WT, but not p53R175H
and p53R273H, physically binds to SERCA, an interaction that
relies on the C-terminal fragment of p53 (aa 294-393).9 This
domain of p53 is known to accommodate several post-
translational modifications,18 which, at least theoretically, can
modulate its ability to bind (and hence regulate the activity of)
SERCA. However, the C-terminal fragment of p53 was unable
to influence reticular Ca2+ homeostasis and sensitivity to
oxidative stress per se, indicating that this function resides in
another domain of the protein. Of note, the overexpression of
SERCA was sufficient to rescue the sensitivity of Trp53−/−
MEFs to hydrogen peroxide.9 This is in agreement with the
hypothesis that SERCA operates downstream of p53 in the
cascade of events that connects oxidative stress to apoptosis,
although it does not formally exclude that these proteins
operate independently from each other. Finally, Giorgi et al.
checked whether p53 would modulate the activity of SERCA by
altering its oxidation status. Indeed, p53WT turned out to
respond to doxorubicin by limiting the inhibitory sulfenylation
of cysteine residues in SERCA, an activity that was not
displayed by p53R273H.9 Thus, cytosolic p53 influences reticular
Ca2+ homeostasis by regulating the pump activity of SERCA.
To test the relevance of their findings in vivo, Giorgi and
collaborators developed a novel technological platform for the
intravital imaging of Ca2+ waves, based on skinfold chambers
and the ratiometric Ca2+ probe Fura-2.8 Using this approach,
Giorgi et al. were able to monitor Ca2+ waves elicited by
photodynamic therapy (PDT), an anticancer regimen relying
on the administration of an ER-targeted photosensitizer
coupled to the exposure of neoplastic lesions to visible
light (which promotes oxidative stress), in tumor masses
developing s.c. in mice. In particular, they tested the ability
of neoplastic lesions formed by HRASG12V-expressing
Trp53+/+ or Trp53−/− MEFs to respond to PDT by generating
Ca2+ fluxes that ignite the intrinsic pathway of apoptosis.
Confirming their in vitro observations, the authors found that
Trp53+/+, but not Trp53−/−, tumors respond to PDT by
accumulating Ca2+ ions within the mitochondrial matrix and,
as a consequence, initiate the apoptotic program. Moreover,
they confirmed that the overexpression of SERCA rescue the
sensitivity of Trp53−/− tumors to PDT-elicited oxidative stress,
as does the overexpression of the mitochondrial calcium
uniporter (MCU),8 the protein that is responsible for the uptake
of cytosolic Ca2+ by mitochondria.19 Finally, they demon-
strated that intercepting intracellular Ca2+ ions with the cell-
permeant chelator BAPTA-AM significantly reduces the
sensitivity of Trp53+/+ cancers to PDT.8 Taken together, these
data indicate that the regulation of reticular Ca2+ homeostasis
by p53 determines the response of established neoplasms to
clinically employed inducers of oxidative stress.
Figure 1 Oncosuppressive functions of p53. In physiological conditions, p53
regulates the expression of several enzymes involved in bioenergetic metabolism and
redox balance, hence preserving intracellular homeostasis (not shown). Moreover,
p53 respond to various stimuli, including oncogenic stress as well as chemo- and
radiotherapy, by orchestrating a cell-wide oncosuppressive program with transcrip-
tional and non-transcriptional branches. In particular, when homeostasis cannot be
restored, p53 (1) transactivates several genes coding for cell cycle-arresting factors
(e.g., CDKN1A) and proapoptotic proteins (e.g., BAX); (2) physically bind to distinct
members of the Bcl-2 protein family at mitochondria (including BAX, BCL-2 and BCL-
XL), hence promoting mitochondrial outer membrane permeabilization (MOMP)-
driven apoptosis; and (3) physically interacts with SERCA at the endoplasmic
reticulum (ER), hence facilitating the accumulation of Ca2+ ions within the ER lumen.
Such an increase in reticular Ca2+ concentrations exacerbates pro-apoptotic Ca2+
waves elicited in the course of adaptive stress responses, hence reducing the
resistance of cells to several perturbations of homeostasis. MCU, mitochondrial
calcium uniporter; MAMs, mitochondria-associated ER membranes
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The recent papers from Paolo Pinton’s laboratory add yet
another entry to the ever growing list of p53 functions, the
direct control of reticular Ca2+ homeostasis. However, several
questions remain to be addressed. First, which domain of p53
is responsible for this functional effect (and not just for the
interaction between p53 and SERCA)? Second, do com-
pounds that transcriptionally reactivate mutant p53 variants,
such as thiosemicarbazone derivatives,20 also restore its
ability to activate SERCA? Third, what is the role of anti-
apoptotic members of the Bcl-2 protein family, which (at least
in part) localize to the ER and modulate Ca2+ homeostasis, in
this process? Shedding light on these and other incognita may
drive the development of novel strategies for resensitizing p53-
deficient tumors to therapy based on the restoration of Ca2+
fluxes. Now, also p53 surfs the Ca2+ wave.
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